PharmaCyte Biotech (PMCB) Change in Account Payables (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Change in Account Payables of -$842561.0 for Q2 2026, down 882.66% year-over-year from $107653.7 in Q2 2025, and down 571.38% quarter-over-quarter from $178743.0 in Q1 2026.
PharmaCyte Biotech (PMCB) Change in Account Payables (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Change in Account Payables for 17 consecutive years, with -$842561.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Account Payables fell 882.66% year-over-year to -$842561.0; the TTM figure through Apr 2026 stood at -$128102.0 (down 1402.51% YoY), while the FY2026 annual figure was -$128102.0, down 1402.51% from the prior year.
- Change in Account Payables fell to -$842561.0 in Q2 2026 per PMCB's latest filing, from $178743.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $589849.0 in Q3 2023 and bottomed at -$842561.0 in Q2 2026.
- Historically, Change in Account Payables has averaged -$2877.9 across 5 years, with a median of $89252.0 in 2022.
- On a YoY basis, Change in Account Payables climbed as much as 5525.14% in 2022 and fell as far as 6606.06% in 2022.
- PharmaCyte Biotech's Change in Account Payables stood at $302251.0 in 2022, then plunged by 295.85% to -$591967.0 in 2023, then jumped by 65.31% to -$205357.0 in 2024, then jumped by 328.73% to $469711.0 in 2025, then sank by 279.38% to -$842561.0 in 2026.
- Business Quant data shows PMCB's Change in Account Payables at -$842561.0 in Q2 2026, $178743.0 in Q1 2026, and $469711.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | -842,561.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -842,561.00 |
| Apr 30, 2026 | -842,561.00 |
| Jan 31, 2026 | 178,743.00 |
| Jan 31, 2026 | 178,743.00 |
| Oct 31, 2025 | 469,711.00 |
| Oct 31, 2025 | 469,711.00 |
| Jul 31, 2025 | 66,005.00 |
| Jul 31, 2025 | 66,005.00 |
| Apr 30, 2025 | -85,743.00 |
| Apr 30, 2025 | -85,743.00 |
| Jan 31, 2025 | 136,353.00 |
| Jan 31, 2025 | 136,353.00 |
| Oct 31, 2024 | -205,357.00 |
| Oct 31, 2024 | -205,357.00 |
| Jul 31, 2024 | 164,582.00 |
| Jul 31, 2024 | 164,582.00 |
| Apr 30, 2024 | -94,828.00 |
| Apr 30, 2024 | -94,828.00 |
| Jan 31, 2024 | 358,036.00 |
| Jan 31, 2024 | 358,036.00 |